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Abstract
In the direct-acting antiviral (DAA) era for hepatitis C virus (HCV) infection, sustained virological response (SVR) is very 
high, but close attention must be paid to the possible occurrence of hepatocellular carcinoma (HCC) and reactivation of 
hepatitis B virus (HBV) in patients with co-infection who achieved SVR in short term. HCC occurrence was more often 
observed in patients with previous HCC history. We found occurrence of HCC in 178 (29.6%) of 602 patients with previ-
ous HCC history (15.4 months mean follow-up post-DAA initiation) but, in contrast, in only 604 (1.3%) of 45,870 patients 
without previous HCC history (18.2 months mean follow-up). Thus, in these guidelines, we recommend the following: in 
patients with previous HCC history, surveillance at 4-month intervals for HCC by ultrasonography (US) and tumor markers 
should be performed. In patients without previous HCC history, surveillance at 6- to 12-month intervals for HCC including 
US is recommended until the long-term DAA treatment effects, especially for the resolution of liver fibrosis, are confirmed. 
This guideline also includes recommendations on how to follow-up patients who have been infected with both HCV and 
HBV. When HCV was eradicated in these HBsAg-positive patients or patients with previous HBV infection (anti-HBc and/
or anti-HBs-positive), it was shown that HBV reactivation or HBV DNA reappearance was observed in 67 (41.4%) of 162 
or 12 (0.9%) of 1317, respectively. For these co-infected patients, careful attention should be paid to HBV reactivation for 
24 weeks post-treatment.
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Abbreviations
HCV  Hepatitis C virus
HBV  Hepatitis B virus
GT  Genotype
HCC  Hepatocellular carcinoma
DAAs  Direct-acting antivirals
SVR  Sustained virological response
EOT  End of treatment
US  Ultrasonography
AFP  α-Fetoprotein
AFP-L3  Lens culinaris agglutinin (LCA)-reactive AFP 
isoform
DCP  Des-γ-carboxy prothrombin
Introduction
Hepatocellular carcinoma (HCC) due to hepatitis C virus 
(HCV) infection is one of the major causes of liver-related 
death [1, 2]. Eradication of HCV could reduce the occur-
rence of HCC, as demonstrated by the long-term follow-
up of patients who achieved sustained virological response 
(SVR) in the interferon era [3–5]. Thus, SVR could be the 
goal of antiviral therapy for HCV.
In the interferon era, as the duration of interferon-based 
therapy was longer than that of DAA therapy, the occur-
rence of HCC has occasionally been observed during the 
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treatment. But these cases were omitted from studies or 
ignored by regarding them as pre-existing, and they were 
therefore unrelated to the interferon treatment [5, 6].
Now, in the age of DAAs, extremely high SVR rates, 
sometimes even 100%, have been reported [7–17]. However, 
there have been several reports on the unexpectedly high 
rate of early HCC occurrence despite the virus eradication 
[18–35]. In real-life settings, if these are actual cases, this 
incidence could be a shocking event to patients as well to 
attending physicians. This prompted us to collect data and 
provide a compact APASL practice guidelines.
In addition, in Asian countries, co-infections of HBV and 
HCV are more frequently observed. We are likely the first to 
elucidate the effects of DAA on the replication of HBV by 
such a high SVR for HCV. Therefore, we have also proposed 
a compact recommendation on how to follow co-infected 
patients.
Part I
Risk factors for the occurrence of HCC
These days, most patients seen at outpatient clinics are 
those whose HCV has been eradicated by the use of DAAs. 
Although more recent clinical studies and real-world studies 
have reported that DAA therapy decreased the risk of both 
de novo HCC and recurrent HCC in both cirrhotic and non-
cirrhotic patients with HCV infection, several preliminary 
studies have dealt with the risk factors for the occurrence 
of HCC [29, 32, 34, 35]. These studies revealed that male 
gender, older age, alcohol abuse, diabetes mellitus, and the 
existence of cirrhosis are associated with the occurrence of 
Table 1  Risk factors and odds ratio for HCC in direct-acting antiviral (DAA) combination-treated patients [29, 32, 34, 35]
AFP α-fetoprotein, EOT end of treatment, n number
Risk factors for HCC Odds ratio (95% CI), n, p value [Refs.]
Cirrhosis 4.73 (3.34–6.68), total n = 19,581, HCC (n, cirrhosis, yes/no = 139/44), < 0.0001 [29]
Previous HCC history 2.64 (0.90–7.74), total n = 864, HCC (n, previous HCC history, yes/no = 24/17), 0.075 [32]
Male gender 2.63 (0.65–10), total n = 19,581, HCC (n, male, yes/no = 181/2), 0.17 [29]
2.09 (0.73–5.98), total n = 864, HCC (n, male, yes/no = 26/15), 0.167 [32]
1.49 (0.91–2.44), total n = 2249, HCC (n, male, yes/no = 55/23), 0.11 [35]
Alcohol abuse 1.56 (1.11–2.18), total n = 19,581, HCC (n, alcohol, yes/no = 124/59), 0.01 [29]
Older age 1.30 (0.96–1.76), total n = 19,581, HCC (n, >=65, yes/no = 71/112), 0.08 [29]
Diabetes mellitus 1.28 (0.92–1.78), total n = 19,581, HCC (n, diabetes, yes/no = 96/87), 0.13 [29]
Drug use 1.27 (0.91–1.75), total n = 19,581, HCC (n, drug, yes/no = 91/92), 0.15 [29]
Bilirubin 1.25 (0.97–1.62), total n = 2249, HCC (n = 78), 0.08 [35]
Low albumin 1.92 (1.16–3.22), total n = 2249, HCC (n = 78), 0.010 [35]
EOT-AFP (=>9 ng/mL) 1.19 (1.07–1.34), total n = 1523, HCC (n = 20), 0.0027 [34]
Low platelet count 1.01 (1.01–1.02), total n = 2249, HCC (n = 78), 0.011 [35]
Fig. 1  Surveillance/monitoring algorithm for patients with hepati-
tis C virus and sustained virological response by direct-acting anti-
virals (DAAs). HCC Hx history of hepatocellular carcinoma, Adv 
Fibrosis advanced liver fibrosis, US ultrasonography, T Markers: 
α-fetoprotein  (AFP), lens culinaris agglutinin (LCA)-reactive AFP 
isoform (AFP-L3) and/or des-γ-carboxy prothrombin (DCP)
Fig. 2  Surveillance/monitoring algorithm for patients co-infected 
with hepatitis C virus and hepatitis B virus (HBV) and treated with 
direct-acting antivirals (DAAs). HCC Hx history of hepatocellular 
carcinoma, Adv Fibrosis advanced liver fibrosis, NUCs nucleos(t)
ides, HBsAg hepatitis B virus surface antigen, anti-HBc ant-hepatitis 
B virus core antibody, HBVr HBV reactivation and/or HBV DNA 
reappearance, +ve positive, -ve negative
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HCC (Table 1) [29, 32, 34, 35]. Most of these studies were 
conducted 1–2 years after DAA treatment [11, 33]. Simi-
lar factors were also shown to be associated with increased 
HCC risk during the interferon era [36, 37].
However, in addition to the abovementioned parameters, 
there is some dispute regarding the difference in occur-
rence of HCC between patients with and without previous 
HCC history [19–21, 38]. Thus, we conducted a literature 
search, investigating the occurrence of HCC in DAA-treated 
patients with and without previous HCC history (Table 2) 
[18–35]. A summary of the collected data is described in 
the following sections.
Occurrence of HCC in patients without previous HCC 
history
The occurrence of HCC after SVR in patients without previ-
ous HCC history was reported in ten studies (Table 3). In 
those 10 studies, the total number of SVR patients ranged 
from 54 to 19,909 patients (mean: 4587 patients). The mean 
follow-up period of those studies was 18.2 months (range 
9–36 months) post-DAA initiation. The overall occurrence 
rate of HCC after SVR in 45,870 patients without previous 
HCC history was 604 (1.3%) (range 0.9–7.4%) (Table 3) [21, 
23, 26, 28–30, 32–35]. Thus, the annual occurrence rate of 
SVR patients by DAA without previous HCC history is no 
different from that of the interferon era [3–5, 39–41].
Therefore, the same guidelines and recommendations as 
were present in the time of interferon may apply to patients 
treated by DAAs, if there is no previous experience of HCC. 
Of course, regular follow-ups are necessary, according to the 
routinely set rules of the interferon era, especially among 
HCV patients with advanced liver fibrosis or cirrhosis 
(Table 3) [42, 43].
Occurrence of HCC in patients with previous HCC 
history
The occurrence of HCC after DAA treatment and SVR in 
patients with previous HCC history was reported in six stud-
ies (Table 4) [21, 24, 25, 28, 32, 34]. The total number of 
SVR patients ranged from 53 to 155 patients (mean: 100 
patients). The mean follow-up period of these studies was 
15.4 months (range 9–28 months) post-DAA initiation. 
The overall occurrence rate of HCC after DAA treatment 
and SVR in patients with previous HCC history was 29.6% 
(178/602) (range 17.1–71.6%) (Table 4) [21, 24, 25, 28, 32, 
34].
The very high incidence of HCC occurrence during 
and right after DAA treatment suggests that very careful 
Table 2  Occurrence of hepatocellular carcinoma (HCC) in patients with direct-acting antiviral (DAA) treatment and sustained virological 
response (SVR) [18–35]
n number
Authors (year) [references] Total SVR patients 
(n)
Observation periods (mean months 
post-DAA initiation)




Minami et al. (2016) [18] 22 5.8 4 (18) 37.2
Reig et al. (2016) [19] 58 5.7 16 (27.6) 58.1
Torres et al. (2016) [20] 84 12 0 (0) 0
Conti et al. (2016) [21] 403 9 26 (6.5) 8.7
Kolly et al. (2017) [22] 47 12 27 (57.4) 57.4
Cardoso et al. (2017) [23] 54 18 4 (7.4) 4.9
Calleja et al. (2017) [24] 70 12 21 (30) 30
Ikeda et al. (2017) [25] 155 12 47 (30.2) 30.2
Mettke et al. (2017) [26] 158 17.5 6 (3.8) 2.61
Nakao et al. (2017) [27] 242 6 6 (2.5) 5.0
Nagata et al. (2017) [28] 729 24.6 29 (4.0) 1.95
Kanwal et al. (2017) [29] 19,518 15.8 183 (0.9) 0.68
Ioannou et al. (2017) [30] 19,909 18 280 (1.4) 0.93
Cabibbo et al. (2018) [31] 143 12 24 (16.8) 16.8
Ooka et al. (2018) [32] 864 15 41 (4.7) 3.76
Reddy et al. (2018) [33] 893 36 16 (1.8) 0.60
Ogawa et al. (2018) [34] 1675 17 46 (2.7) 1.91
Calvaruso et al. (2018) [35] 2140 14 64 (3.0) 2.57
Total 47,164 14.6 (5.7–36) 840 (1.8) 14.6 (0–58.1)
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attention should be paid to the possible occurrence of HCC 
in patients with previous HCC history.
Discussion
Risk of HCC occurrence among patients post‑DAA 
treatment
In the interferon era, male gender, older age, and the exist-
ence of cirrhosis and other factors were shown to be associ-
ated with risk factors of HCC occurrence [42, 44, 45]. Also 
in the age of DAAs, similar factors are shown to be associ-
ated with this risk. In other words, the existence of cirrhosis, 
no SVR, male gender, alcohol abuse, older age, and diabetes 
mellitus are risk factors for HCC occurrence (Table 1) [29, 
32, 34, 35]. Surveillance is recommended for SVR patients 
with any histologic stage of HCV with comorbidities, such 
as alcohol abuse and diabetes mellitus [1].
Of note, most importantly, the current survey revealed 
that the existence of previous HCC history is an independ-
ent, very high-risk factor for HCC occurrence post-DAA 
treatment.
In the interferon era, because the treatment duration was 
longer than that of DAA, several studies seemed to exclude 
HCC occurrence during and right after interferon treatment 
when analyzing their data. In fact, during the interferon era, 
many patients with HCC or cirrhosis could not receive inter-
feron treatment. To some extent, this might explain the lower 
occurrence of HCC during or right after antiviral treatment.
It has been reported that several mechanisms may exist 
during and after DAA treatment, such as rapid immuno-
logical changes, that could lead to HCC occurrence [46–50]. 
Changes in cytokines and chemokines have been observed in 
HCC occurrence post-DAA treatment and it is possible that 
they may have affected tumor immunity [46–50].
DAA treatment increased the serum vascular endothe-
lial growth factor (VEGF) level which is significantly 
Table 3  Occurrence of hepatocellular carcinoma (HCC) after direct-acting antiviral (DAA) treatment and sustained virological response (SVR) 
in patients without previous HCC history [21, 23, 26, 28–30, 32–35]
n number
Authors (year) [references] Total SVR patients 
(n)
Observation periods (months 
post-DAA initiation)




Conti et al. (2016) [21] 254 9 7 (2.7) 3.60
Cardoso et al. (2017) [23] 54 18 4 (7.4) 4.93
Mettke et al. (2017) [26] 158 17.5 6 (3.8) 2.61
Nagata et al. (2017) [28] 652 21.6 7 (1.1) 0.61
Kanwal et al. (2017) [29] 19,518 15.8 183 (0.9) 0.68
Ioannou et al. (2017) [30] 19,909 18 280 (1.4) 0.93
Ooka et al. (2018) [32] 769 15 17 (2.2) 1.76
Reddy et al. (2018) [33] 893 36 16 (1.8) 0.60
Ogawa et al. (2018) [34] 1523 17 20 (1.3) 0.92
Calvaruso et al. (2018) [35] 2140 14 64 (3.0) 2.57
Total 45,870 18.2 (9–36) 604 (1.3) 1.92 (0.60–4.93)
Table 4  Occurrence of hepatocellular carcinoma (HCC) after direct-acting antiviral (DAA) treatment and sustained virological response (SVR) 
in patients with previous HCC history [21, 24, 25, 28, 32, 34]
n number
Authors (year) [references] Total SVR patients 
(n)
Observation periods (months 
post-DAA initiation)




Conti et al. (2016) [21] 53 9 38 (71.6) 95.5
Calleja et al. (2017) [24] 70 12 21 (30) 30.0
Nagata et al. (2017) [28] 77 27.6 22 (28.6) 12.4
Ikeda et al. (2017) [25] 155 12 47 (30.3) 30.3
Ooka et al. (2018) [32] 95 15 24 (25.3) 20.2
Ogawa et al. (2018) [34] 152 17 26 (17.1) 12.1
Total 602 15.4 (9–27.6) 178 (29.6) 33.4 (12.1–95.5)
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related to the serum angiopoietin-2 level. These are risk 
factors for HCC occurrence post-DAA treatment [51, 52]. 
Rapid immunological changes, including in NKG2D sys-
tems, are also observed during and after DAA treatment 
[53, 54].
With such drastic “environmental changes” occurring 
in the liver due to the very powerful DAAs, pre-existing 
“occult neoplastic” or “dysplastic” cells may develop into 
classical tumors in a short time period. Ooka et al. reported 
that “dysplastic” nodules detected by ultrasonography (US) 
might turn into hyper-vascular “classical” HCC by rapid 
decrease of the immune surveillance system with rapid elim-
ination of HCV [32, 46, 55]. Studies have proposed that the 
presence of “dysplastic” nodules by US has a much higher 
odds ratio (26 times) than previous HCC history [32, 56].
In fact, approximately 50% of HCC occurrence and recur-
rence cases are observed during and 1–2 years after DAA 
treatment [21, 33]. Although it is well known that patients 
with mild/no fibrosis and SVR have a lower risk of devel-
oping HCC, population-based studies were different from 
clinical practice guidelines. So, we recommend that, for 
patients with SVR and risk factors of HCC, surveillance for 
HCC should be conducted at shorter intervals, and especially 
within 2 years post-DAA treatment.
How to follow these patients? Among imaging modalities 
(US, CT, and MRI), US might be the most cost-effective and 
easily available modality.
The prognosis of HCC depends on earlier-stage detection 
and earlier treatment [1]. In addition to US, measurement 
of tumor markers may play a more important role in HCC 
screening. Among tumor markers for the diagnosis of HCC, 
measurement of AFP has been performed for decades [57, 
58], although with some dispute regarding its significance. 
However, there have been numerous studies regarding mul-
tiple tests including lens culinaris agglutinin (LCA)-reactive 
AFP isoform (AFP-L3), which can differentiate an increase 
in AFP due to HCC from that in patients with benign liver 
disease. In addition, des-γ-carboxy prothrombin (DCP) is a 
very powerful measure for detecting early and small tumors 
[59–65]. These studies are mostly from Japan, and these 
two tests, AFP-L3 and DCP, could not be validated as they 
have not been available in many countries. However, AFP, 
AFP-L3, and DCP tests have now become increasingly avail-
able in many Asian countries. Thus, we recommended the 
measurements of these markers.
Once a blood test result is abnormal, further imaging 
modalities [gadolinium ethoxybenzyl diethylenetriamine 
pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI and/or 
dynamic CT] should be performed for the potential diagno-
sis of HCC occurrence [1, 32].
Thus, in patients with previous HCC history, surveillance 
of shorter 4-month intervals for HCC, including US with 
AFP, AFP-L3, and/or DCP, should be performed [1].
After successful eradication of HCV, regular follow-up 
of HCC, esophageal varices, and other complications of 
advanced liver fibrosis will be necessary if they existed at 
pre-treatment [66–68].
#1 Consensus statements and recommendations 
on follow‑up of DAA‑treated virus‑eradicated 
HCV‑infected patients
1. In patients without advanced liver fibrosis, or cirrhosis 
and without previous HCC history
(1) Before, during, and approximately 2 years after 
the end of treatment (EOT) with DAA, surveil-
lance at 6-month intervals for HCC, including 
ultrasonography (US) with or without tumor 
markers, should be performed (C-2).
(2) After 2 years, surveillance at 12-month intervals 
for HCC, including US with or without AFP, 
could be performed (C-2).
2. In patients with advanced liver fibrosis or cirrhosis and 
without previous HCC history
  Surveillance at 6-month intervals for HCC, includ-
ing by US with AFP, lens culinaris agglutinin (LCA)-
reactive AFP isoform (AFP-L3) and/or des-γ-carboxy 
prothrombin (DCP) should be performed (A-1).
3. In patients with previous HCC history
  Surveillance at 4-month intervals for HCC, including 
by US with AFP, AFP-L3 and/or DCP, should be per-
formed. In these cases, contrast-enhanced US (CEUS), 
dynamic CT, dynamic MRI or gadolinium ethoxybenzyl 
diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-
enhanced MRI could be added (A-2).
4. SVR patients with alcohol abuse and/or diabetes mel-
litus should undergo surveillance for HCC regularly (A-
1).
5. In patients with advanced liver fibrosis or cirrhosis, 
screening for esophageal and gastric varices by endos-
copy should be performed especially if present at pre-
treatment (A-1).
Grading of evidence and recommendations are shown in 
Supplementary Table 1.
Part II
HBV reactivation in patients with HCV and HBV 
co‑infection
HBV infection is one of the major health problems in 
the world, with the highest rates being in Africa and the 
654 Hepatology International (2019) 13:649–661
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Asia–Pacific region [69]. Evaluation for HBV infection was 
also recommended for all persons with active HCV infection 
by the US Food and Drug Administration in 2004. However, 
the exact prevalence and characteristics of HBV DNA reap-
pearance and clinical “reactivation” among patients treated 
by DAAs are not known in detail.
Therefore, we collected data from 14 studies on HBV 
DNA reappearance and clinical reactivation in HBV and 
HCV co-infected patients treated by DAAs (Table  5) 
[70–78].
HBsAg‑positive group
Of these 14 studies, 8 reported the results of HBV DNA 
reappearance and clinical reactivation in HBsAg-positive 
patients treated by DAAs (Table 5) [70–77]. The number 
of patients enrolled in those 8 studies ranged from 4 to 
109 patients (mean 20) and the mean observation period 
was 3 months post-EOT. The overall occurrence rate of 
HBV DNA reappearance and clinical reactivation among 
162 patients treated by DAA was 41.4% (67/162) (range 
25–100%). Thus, among HBsAg-positive patients, HBV 
DNA reappearance and reactivation are the frequent events 
through at least 12 weeks after EOT (Table 5).
HBsAg‑negative group (anti‑HBc‑ and/or anti‑HBs‑positive 
group)
Of the 14 studies (Table 5), 6 studies reported results on 
HBV DNA reappearance and clinical reactivation in HBsAg-
negative, but positivity for anti-hepatitis B core (anti-HBc) 
antibody and/or anti-hepatitis B surface (anti-HBs) antibody 
at baseline [71–73, 75, 76, 78].
The number of patients enrolled in those 6 studies ranged 
from 57 to 765 patients (mean 219.5) and the mean observa-
tion period was 3 months post-EOT. The overall occurrence 
rate of HBV DNA reappearance and clinical reactivation 
among 1317 patients treated by DAAs was 0.91% (12/1317) 
(range 0–6.3%) (Table 5). Thus, in HBsAg-negative patients 
but positive for anti-HBc antibody and/or anti-HBs antibody 
Table 5  Hepatitis B virus (HBV) reactivation or HBV DNA reappearance in patients with HBV and hepatitis C virus (HCV) co-infection after 
direct-acting antiviral (DAA) treatment [70–78]
HBsAg hepatitis B surface antigen, anti-HBc anti-hepatitis B core antibody, anti-HBs anti-hepatitis B surface antibody, EOT end of treatment, n 
number
a Three patients (one with cirrhosis and two without cirrhosis) began anti-HBV treatment: one entecavir (ETV) and two tenofovir disoproxil 
fumarate (TDF)
b Three patients (one with cirrhosis and two without cirrhosis) began TDF
c One cirrhotic patient began TDF
d Two patients, one had hepatic failure and one had icteric hepatitis
e One icteric patient began ETV
Authors (year) [references] Total patients (n) Observation periods 
(months post-EOT)
Patients with increases of HBV 
DNA greater than 1 log10 IU/mL 
or HBV DNA reappearance [n (%)]
Monthly incidence of HBV reacti-
vation or HBV DNA reappearance 
(%/month)
HBsAg-positive patients
Gane et al. (2016) [70] 8 3 7 (87.5) 29.2
Doi et al. (2017) [71] 4 3 2 (50) 16.7
Kawagishi et al. (2017) [72] 4 3 2 (50) 16.7
Yeh et al. (2017) [73] 7 3 7 (100)e 33.3
Mucke et al. (2017) [74] 8 3 4 (50)b 16.7
Wang et al. (2017) [75] 10 3 3 (33.3)d 11.1
Tamori et al. (2018) [76] 12 3 3 (25)c 8.3
Liu et al. (2018) [77] 109 3 39 (35.8)a 13
Total 162 3 67 (41.4) 18.1 (8.33–33.3)
HBsAg-negative patients positive for anti-HBc antibody and/or anti-HBs antibody
Yeh et al. (2017) [73] 57 3 0 (0) 0
Wang et al. (2017) [75] 124 3 0 (0) 0
Doi et al. (2017) [71] 155 3 3 (1.9) 0.63
Kawagishi et al. (2017) [72] 153 3 4 (2.6) 0.87
Ogawa et al. (2018) [78] 63 3 4 (6.3) 2.1
Tamori et al. (2018) [76] 765 3 1 (0.1) 0.33
Total 1317 3 12 (0.91) 0.61 (0–2.1)
655Hepatology International (2019) 13:649–661 
1 3
at baseline; HBV reactivation and/or HBV DNA reappear-
ance are rare events through 12 weeks after EOT (Table 5).
Discussion
Clinical pictures of HBV reactivation
HBsAg‑positive group
Before the rituximab (humanized anti-CD20 monoclonal 
antibody) era, Lau et al. reported that among 15 HBsAg-
positive patients with lymphoma treated with chemotherapy 
but deferred prophylactic lamivudine therapy, 8 (53%) had 
HBV reactivation defined as an increase of serum HBV 
DNA to more than 10 times of baseline [79]. Of these eight 
patients, seven (87.5%) had ‘hepatitis’, defined as a more 
than threefold increase of serum ALT on two consecutive 
determinations at least 5 days apart. Of these seven patients, 
anicteric and icteric hepatitis and hepatic failure were 5, 1, 
and 1, respectively [79]. Thus, of HBsAg-positive patients 
with lymphoma treated by chemotherapy without nucleos(t)
ide analogs, 6.7% (1/15) had hepatic failure [79]. They also 
observed that, among 15 patients with lymphoma who 
received lamivudine 1 week before chemotherapy, none 
had HBV reactivation after chemotherapy [79]. Lok et al. 
also observed 18 HBV reactivations (67%) [6 icteric hepa-
titis (22%); 1 non-fatal hepatic failure (3.7%); and 1 death 
(3.7%)] among 27 Chinese patients who underwent induc-
tion cytotoxic therapy without prophylaxis for HBsAg-pos-
itive malignant lymphoma [80].
After rituximab was introduced as a potent drug for 
patients with malignant lymphoma, reactivation of HBV 
has been repeatedly shown in HBsAg-positive patients [81]. 
Wang et al. reported that rituximab/chemotherapy induced 
hepatic dysfunction in 13 (33%) of 40 HBsAg-positive 
patients with diffuse large B cell lymphoma [82].
HBV reactivation has also been reported in HBsAg-pos-
itive solid cancer patients who underwent chemotherapy or 
other molecular target therapies [69]. Among HBsAg-posi-
tive breast cancer patients receiving chemotherapy, the rates 
of HBV reactivation in patients without or with prophylac-
tic lamivudine were 28.6% and 0%, respectively [83]. HBV 
reactivation during chemotherapy occurred independently 
of lymphoma (odds ratio: 5.0), breast cancer (odds ratio: 
4.2), steroid use (odds ratio: 2.7), and HBV DNA positive 
at baseline (odds ratio: 8.4) [84].
Thus, APASL HBV guidelines have recommended 
that prophylactic nucleos(t)ide therapy should be given to 
HBsAg-positive cancer patients who receive cytotoxic and 
immunosuppressive therapy, regardless of HBV DNA levels 
for 12 months after cessation [69].
Regarding the treatment by DAAs for those co-infected 
with HBV and HCV, a variety of events, ranging from 
asymptomatic HBV reactivation/HBV DNA reappearance to 
clinically symptomatic reactivation characterized by eleva-
tion in HBV DNA and ALT were reported [70–77].
Collected results of eight studies of HBsAg-positive and 
co-infected patients treated with DAAs for HCV infection 
indicated that the rates of HBV reactivation were similar 
to HBsAg-positive patients with malignant lymphoma and 
cancer patients treated with cytotoxic drugs (~ 40%) [85, 86] 
(also see Table 5).
Regarding the severity of liver disease induced by this 
HBV reactivation in HBsAg-positive patients treated with 
DAAs, only limited data are available [75, 77, 87–89]. Ber-
soff-Matcha et al. reported that two cases with liver failure 
resulted in one death and one case of liver transplantation 
[87]. Wang et al. also reported one HBsAg-positive patient 
with liver failure due to HBV reactivation although most 
reported cases were asymptomatic increases of HBV DNA 
and/or ALT in the absence of concomitant liver injury [75].
Of note, Liu et al. reported that two patients had concomi-
tant elevation of HBV DNA level with ALT elevation > 2 
times the upper limit of normal at post-treatment week 48, 
of whom one commenced treatment with entecavir at post-
treatment week 53 following the onset of malaise, anorexia, 
and nausea associated with sclera jaundice [77]. Holmes 
et al. reviewed two HBsAg-positive, co-infected patients 
who were treated by DAAs for HCV infection, and had 
fulminant hepatic failure and death: one was a 57-year-old 
female who was treated with daclatasvir plus asunaprevir, 
had HBV reactivation at week 8 from the start of DAAs, and 
she was treated with entecavir; the other was a 73-year-old 
female who was treated with daclatasvir plus asunaprevir, 
had HBV reactivation at week 7 from the start of DAAs, 
and she had stopped entecavir prior to the commencement 
of DAA therapy [88].
At present, we do not know the risk factors of HBV reac-
tivation and associated liver failure, although several fac-
tors such as HBsAg levels and HBV DNA levels have been 
reported [76, 90].
For the safety of HBsAg-positive patients treated by 
DAAs, we recommend that prophylactic nucleos(t)ide ther-
apy should be given before starting DAA therapy; nonethe-
less, further studies may also be needed to determine the 
duration of prophylactic nucleos(t)ide therapy.
HBsAg‑negative, but positive for anti‑HBc and/or anti‑HBs 
group
Although the elimination of HBsAg is one of the goals in 
the treatment of HBV infection, HBV DNA reappeared in 
15–33% patients after HBsAg seroclearance in the natural 
history of HBV infection and in post-anti-HBV treatment 
656 Hepatology International (2019) 13:649–661
1 3
[91]. So, it is possible that HBV reactivation and/or HBV 
DNA reappearance may occur in patients of this group 
treated by DAAs, as well as patients who receive immuno-
suppressants or anti-cancer drugs (Table 6).
With the administration of rituximab without antivi-
ral treatment, clinical HBV reactivation was estimated at 
6.3% in HBsAg-negative/anti-HBc-positive patients with 
lymphoma [92]. Prior to use of rituximab, Lok et al. also 
observed 10 HBV reactivations (14%) [1 icteric hepatitis 
(2%); 1 non-fatal hepatic failure (2%); and no death (0%)] 
of 72 HBsAg-negative patients with malignant lymphoma 
treated by chemotherapy without prophylactic treatment of 
nucleos(t)ide analogs (Table 6) [80].
Thus, in the rituximab era, once HBsAg-negative patients 
who received rituximab including chemotherapy for malig-
nant lymphoma had HBV reactivation (6.3–17.9%) (Table 6) 
[92–94], higher mortality rates (12.5–50%) were seen [95].
In breast cancer, HBV fetal reactivation was occasion-
ally observed in HBsAg-negative patients who underwent 
chemotherapy [96]. Kim et al. reported that HBV reactiva-
tion occurred in 1 (0.3%) of 321 HBsAg-negative and anti-
HBc-positive patients with solid cancers during anti-cancer 
chemotherapy [97]. Hagiwara et al. reported that HBV reac-
tivation occurred in 2 (7.4%) of 27 HBsAg-negative and 
anti-HBc/anti-HBs-positive patients with solid cancers dur-
ing anti-cancer chemotherapy [98].
Jun et al. reported that 2 (10%), 8 (5.3%), 4 (5.5%), and 2 
(0.9%) HBV reactivations were observed in 20 HBsAg(−)/
anti-HBc(+)/anti-HBs(−), 151 HBsAg(−)/anti-HBc(+)/anti-
HBs(+), 73 HBsAg(−)/anti-HBc(−)/anti-HBs(−), and 227 
HBsAg(−)/anti-HBc(−)/anti-HBs(+) patients undergoing 
hematopoietic stem cell transplantation, respectively [99]. 
Of note, the incidence of HBV reactivation in these HBsAg-
negative patients was not low (5.9%) [99, 100], although 
most patients with solid cancers remained unscreened for 
HBV-resolved infection [101, 102].
A summary of six studies of HBsAg-negative cases indi-
cates that the overall occurrence rate of HBV reactivation 
and/or HBV DNA reappearance is lower (0.91%) (Table 5).
The prevalence rates of HBV reactivation and/or HBV 
DNA reappearance in patients of the HBsAg-negative/anti-
HBc-positive group by DAAs seem equal to or less than 
those with chemotherapy for breast cancer, one of the non-
hematologic malignancies.
Regarding the severity of liver disease induced by this 
HBV reactivation in HBsAg-negative patients treated 
by DAA, only limited data are available [103, 104]. Two 
HBsAg-negative patients who developed hepatic failure after 
DAA treatment have been reported (Table 7) [103, 104]. We 
do not know the exact risk factors of HBV reactivation in 
HBsAg-negative patients treated with DAAs although sev-
eral factors have been reported [71–73, 75, 76, 78].
There are no standard management regimens for HBV 
reactivation among HBsAg-negative patients, even for those 
treated with rituximab including chemotherapy. It has been 
reported that monthly monitoring of HBV DNA is useful 
for preventing HBV reactivation-related hepatitis among B 
cell non-Hodgkin lymphoma patients with resolved HBV 
infection following rituximab plus corticosteroid including 
chemotherapy [105].
Physicians should be aware of the risk of HBV reactiva-
tion in HBsAg-negative patients. Although further studies 
are needed to compare the efficacy and cost effectiveness 
of different preventive strategies, we should at least per-
form careful monitoring of these patients, and if needed, we 
should administer nucleos(t)ide analogs against HBV DNA 
reactivation/reappearance. Regarding nucleos(t)ide analogs, 
as lamivudine and telbivudine are limited, entecavir or teno-
fovir would be preferred.
#2 Consensus statements and recommendations 
on follow‑up of HBV and HCV co‑infected patients 
treated with DAA in Asia–Pacific region
1. Before starting DAA treatment, HBsAg should be exam-
ined in high endemic areas of HBV infection (A-1).
2. In HBsAg-positive patients with advanced fibrosis, 
cirrhosis or previous HCC, pre-emptive nucleos(t)ide 








Incidence [n, (%)] Authors (year) [references]
Lymphoma (without rituximab-based regimens) NA 72 10 (14%) Lok et al. (1991) [80]
Lymphoma (with rituximab-based regimens) NA 39 7 (17.9%) Huang et al. (2013) [93]
Hematologic malignancy (with rituximab-based regimens) NA 28 3 (10.7%) Buti et al. (2014) [94]
Lymphoma (with rituximab-based regimens) NA 578 36 (6.3%) Mozessohn et al. (2015) [92]
Solid cancer NA 27 2 (7.4%) Hagiwara et al. (2012) [98].
Solid cancer NA 321 1 (0.3%) Kim et al. (2014) [97]
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analog treatment should be started to prevent HBV reac-
tivation (A-1).
3. In HBsAg-positive patients without advanced fibro-
sis, cirrhosis or previous HCC history, pre-emptive 
nucleos(t)ide analog treatment is effective for HBV 
infection (A-1), or close monitoring should be recom-
mended during DAA treatment and through 24 weeks 
after EOT (B-1). Stopping should follow APASL HBV 
guidelines.
4. In HBsAg-negative patients who are positive for anti-
HBc antibody and/or anti-HBs antibody when abnormal 
liver function tests are observed during DAA treatment 
and after EOT, HCV RNA, HBsAg and HBV DNA 
should be examined. Nucleos(t)ide analogs should be 
used to treat HBV reactivation (B-1).
Grading of evidence and recommendations are shown in 
Supplementary Table 1.
Conclusion
During DAA treatment, host immunological changes may 
occur although DAA treatment can lead to higher SVR rates 
with shorter treatment duration and less serious adverse 
events in most patients infected with HCV [10]. First, we 
have created guidelines for the monitoring of HCC occur-
rence based on its accumulated data for it (Fig. 1). Second, 
we have constructed compact guidelines for patients with 
HBsAg and anti-HBc and/or anti-HBs antibody (Fig. 2). 
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